Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses - Summary - MDSpire

Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses

  • By

  • Pietro Annovazzi

  • Marinella Clerico

  • Eleonora Cocco

  • Antonella Conte

  • Girolama Alessandra Marfia

  • Marco Salvetti

  • Valentina Tomassini

  • Rocco Totaro

  • Diego Centonze

  • April 28, 2026

  • 0 min

Share

Objective:

To correct the funding statement in the article regarding the enhancement of the endocannabinoid system in treating residual disease in relapse-free multiple sclerosis.

Key Findings:
  • The original funding statement incorrectly stated that no financial support was received.
  • The updated statement confirms that financial support was provided for the work and publication.
Interpretation:

The correction emphasizes the importance of transparency regarding funding sources in scientific research.

Limitations:
  • The correction does not address any scientific content or findings of the original article.
Conclusion:

The article has been updated to reflect accurate funding information, ensuring clarity and transparency.

Original Source(s)

Correction: Improving the Endocannabinoid System for Addressing Residual Disease in Multiple Sclerosis Without Relapses

  • by Pietro Annovazzi, Marinella Clerico, Eleonora Cocco, Antonella Conte, Girolama Alessandra Marfia, Marco Salvetti, Valentina Tomassini, Rocco Totaro, Diego Centonze

  • April 28, 2026

Related Content

Digging deeper into NINJ1: its multifaceted role in central nervous system diseases

The epidemiological trends of multiple sclerosis among women of child-bearing age: a global analysis from 1990 to 2021 and forecasts to 2040

To Avoid Care Disruptions, Know When the Clock Runs Out on Your Prior Authorization - KFF Health News